StemCyte (永笙-KY) announced on the 22nd that it has signed a contract extension with the U.S. government, prolonging its partnership with the California State Umbilical Cord Blood Collection Program through 2027.

• Regulatory Distinction: As the only Asian and the first Taiwanese private cell therapy company to participate long-term in U.S. federal programs, this extension reaffirms StemCyte’s compliance with the rigorous FDA Biologics License Application (BLA) standards for cord blood products.
• Clinical Pipeline: Beyond its FDA-licensed product REGENECYTE, StemCyte is advancing multiple trials, including a Phase III application for Long COVID and ongoing Phase I/II trials.
• Strategic Value: The partnership ensures a stable supply of high-quality, multi-ethnic cord blood units, positioning StemCyte as a premier, compliant source for the global CDMO and cell therapy industry.

Resource: 永笙-KY多種族臍帶血公庫收集計畫，再獲美國政府補助至2027年